

# Ann M Moyer

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8421564/publications.pdf>

Version: 2024-02-01

73  
papers

1,870  
citations

331670

21  
h-index

289244

40  
g-index

76  
all docs

76  
docs citations

76  
times ranked

2918  
citing authors

#	ARTICLE	IF	CITATIONS
1	OUP accepted manuscript. <i>Clinical Chemistry</i> , 2022, , .	3.2	0
2	Targeted Genotyping in Clinical Pharmacogenomics. <i>Journal of Molecular Diagnostics</i> , 2022, 24, 253-261.	2.8	13
3	Identification of sex-specific genetic associations in response to opioid analgesics in a White, non-Hispanic cohort from Southeast Minnesota. <i>Pharmacogenomics Journal</i> , 2022, , .	2.0	3
4	Late Complications of COVID-19. <i>Archives of Pathology and Laboratory Medicine</i> , 2022, 146, 791-804.	2.5	11
5	Implementation of preemptive DNA sequence-based pharmacogenomics testing across a large academic medical center: The Mayo-Baylor RIGHT 10K Study. <i>Genetics in Medicine</i> , 2022, 24, 1062-1072.	2.4	28
6	Postmortem Assessment of Olfactory Tissue Degeneration and Microvasculopathy in Patients With COVID-19. <i>JAMA Neurology</i> , 2022, 79, 544.	9.0	46
7	SARS-CoV-2 RNA Detection in Formalin-Fixed Paraffin-Embedded (FFPE) Tissue by Droplet Digital PCR (ddPCR). <i>Clinica Chimica Acta</i> , 2022, , .	1.1	6
8	Complement Gene Variant Effect on Relapse of Complement-Mediated Thrombotic Microangiopathy after Eculizumab Cessation. <i>Blood Advances</i> , 2022, , .	5.2	2
9	A reverse-transcription droplet digital PCR assay to detect and quantify SARS-CoV-2 RNA in upper respiratory tract specimens. <i>Journal of Clinical Virology</i> , 2022, 153, 105216.	3.1	11
10	Considerations When Applying Pharmacogenomics to Your Practice. <i>Mayo Clinic Proceedings</i> , 2021, 96, 218-230.	3.0	22
11	HLA-D and PLA2R1 risk alleles associate with recurrent primary membranous nephropathy in kidney transplant recipients. <i>Kidney International</i> , 2021, 99, 671-685.	5.2	24
12	Use of Pharmacogenomics to Guide Proton Pump Inhibitor Therapy in Clinical Practice. <i>Digestive Diseases and Sciences</i> , 2021, 66, 4120-4127.	2.3	7
13	Impact of Pharmacogenomic Information on Values of Care and Quality of Life Associated with Codeine and Tramadol-Related Adverse Drug Events. <i>Mayo Clinic Proceedings Innovations, Quality &amp; Outcomes</i> , 2021, 5, 35-45.	2.4	3
14	NUDT15: A bench to bedside success story. <i>Clinical Biochemistry</i> , 2021, 92, 1-8.	1.9	7
15	Comparison of In Situ Hybridization, Immunohistochemistry, and Reverse Transcription-Droplet Digital Polymerase Chain Reaction for Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2) Testing in Tissue. <i>Archives of Pathology and Laboratory Medicine</i> , 2021, 145, 785-796.	2.5	27
16	Genetic variants related to successful migraine prophylaxis with verapamil. <i>Molecular Genetics &amp; Genomic Medicine</i> , 2021, 9, e1680.	1.2	8
17	Complement testing in the clinical laboratory. <i>Critical Reviews in Clinical Laboratory Sciences</i> , 2021, 58, 447-478.	6.1	4
18	Patient-Derived Xenograft Engraftment and Breast Cancer Outcomes in a Prospective Neoadjuvant Study (BEAUTY). <i>Clinical Cancer Research</i> , 2021, 27, 4696-4699.	7.0	7

#	ARTICLE	IF	CITATIONS
19	Sex differences in type and occurrence of adverse reactions to opioid analgesics: a retrospective cohort study. <i>BMJ Open</i> , 2021, 11, e044157.	1.9	16
20	Establishment and characterization of immortalized human breast cancer cell lines from breast cancer patient-derived xenografts (PDX). <i>Npj Breast Cancer</i> , 2021, 7, 79.	5.2	5
21	Genomics Integration Into Nephrology Practice. <i>Kidney Medicine</i> , 2021, 3, 785-798.	2.0	13
22	Quantitative Alterations in Complement Alternative Pathway and Related Genetic Analysis in Severe Phenotype Preeclampsia. <i>Kidney360</i> , 2021, 2, 1463-1472.	2.1	2
23	Pharmacogenomics education, research and clinical implementation in the state of Minnesota. <i>Pharmacogenomics</i> , 2021, 22, 681-691.	1.3	11
24	Characterization of Reference Materials with an Association for Molecular Pathology Pharmacogenetics Working Group Tier 2 Status: CYP2C9, CYP2C19, VKORC1, CYP2C Cluster Variant, and GGCX. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 952-958.	2.8	9
25	Spectrum of hematological malignancies, clonal evolution and outcomes in 144 Mayo Clinic patients with germline predisposition syndromes. <i>American Journal of Hematology</i> , 2021, 96, 1450-1460.	4.1	19
26	Recommendations for Clinical CYP2D6 Genotyping Allele Selection. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 1047-1064.	2.8	73
27	Mitochondriopathy Manifesting as Inherited Tubulointerstitial Nephropathy Without Symptomatic Other Organ Involvement. <i>Kidney International Reports</i> , 2021, 6, 2514-2518.	0.8	5
28	Acute Kidney Injury in Severe COVID-19 Has Similarities to Sepsis-Associated Kidney Injury. <i>Mayo Clinic Proceedings</i> , 2021, 96, 2561-2575.	3.0	41
29	Nine-gene pharmacogenomics profile service: The Mayo Clinic experience. <i>Pharmacogenomics Journal</i> , 2021, , .	2.0	13
30	Translating Pharmacogenomic Research to Therapeutic Potentials (Bench to Bedside). , 2021, , .		0
31	Pharmacogenomics testing in patients with liver transplant and potential impact on prospective management. <i>Pharmacogenomics</i> , 2021, 22, 1177-1183.	1.3	2
32	Integrating pharmacogenomics into the electronic health record by implementing genomic indicators. <i>Journal of the American Medical Informatics Association: JAMIA</i> , 2020, 27, 154-158.	4.4	29
33	Cohort Profile: The Right Drug, Right Dose, Right Time: Using Genomic Data to Individualize Treatment Protocol (RIGHT Protocol). <i>International Journal of Epidemiology</i> , 2020, 49, 23-24k.	1.9	34
34	Letter Regarding "Fibrillary Glomerulonephritis Is Associated With HLA-DR7 and HLA-B35 Antigens". <i>Kidney International Reports</i> , 2020, 5, 1840-1841.	0.8	3
35	Description of Pharmacogenomic Testing Among Patients Admitted to the Intensive Care Unit After Cardiovascular Surgery. <i>Journal of Intensive Care Medicine</i> , 2020, 36, 088506662094630.	2.8	4
36	Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?. <i>Journal of Personalized Medicine</i> , 2020, 10, 268.	2.5	4

#	ARTICLE	IF	CITATIONS
37	Recommendations for Clinical Warfarin Genotyping Allele Selection. Journal of Molecular Diagnostics, 2020, 22, 847-859.	2.8	39
38	Regulation of sister chromatid cohesion by nuclear PD-L1. Cell Research, 2020, 30, 590-601.	12.0	58
39	Challenges in classification of novel CFH variants in patients with atypical hemolytic uremic syndrome. Thrombosis Update, 2020, 1, 100002.	0.9	3
40	Genotype and Phenotype Concordance for Pharmacogenetic Tests Through Proficiency Survey Testing. Archives of Pathology and Laboratory Medicine, 2020, 144, 1057-1066.	2.5	5
41	Concordance between predicted HLA type using next generation sequencing data generated for non-HLA purposes and clinical HLA type. Human Immunology, 2020, 81, 423-429.	2.4	4
42	&lt;p&gt;Sex Differences in Associations Between CYP2D6 Phenotypes and Response to Opioid Analgesics&lt;/p&gt;. Pharmacogenomics and Personalized Medicine, 2020, Volume 13, 71-79.	0.7	18
43	Determination of Relapse Risk By Complement Gene Variants after Eculizumab Discontinuation in Complement-Mediated Thrombotic Microangiopathy: A Retrospective Review. Blood, 2020, 136, 25-26.	1.4	1
44	Use of pharmacogenetic data to guide individualized opioid prescribing after surgery. Surgery, 2019, 166, 476-482.	1.9	9
45	Consumer-initiated Genetic Testing and Pharmacogenomics. Advances in Molecular Pathology, 2019, 2, 133-142.	0.4	1
46	Recommendations for Clinical CYP2C9 Genotyping Allele Selection. Journal of Molecular Diagnostics, 2019, 21, 746-755.	2.8	84
47	Pharmacogenomic Next-Generation DNA Sequencing: Lessons from the Identification and Functional Characterization of Variants of Unknown Significance in <i>CYP2C9</i> and <i>CYP2C19</i>. Drug Metabolism and Disposition, 2019, 47, 425-435.	3.3	17
48	&lt;p&gt;Concepts Driving Pharmacogenomics Implementation Into Everyday Healthcare&lt;/p&gt;. Pharmacogenomics and Personalized Medicine, 2019, Volume 12, 305-318.	0.7	12
49	Statin therapy: does sex matter?. Menopause, 2019, 26, 1425-1435.	2.0	33
50	Clinical Pharmacogenetics Implementation Consortium Guideline for Thiopurine Dosing Based on <i>TPMT</i> and <i>NUDT15</i> Genotypes: 2018 Update. Clinical Pharmacology and Therapeutics, 2019, 105, 1095-1105.	4.7	428
51	Spontaneous murine tumors in the development of patient-derived xenografts: a potential pitfall. Oncotarget, 2019, 10, 3924-3930.	1.8	11
52	Does Transfusion of Red Blood Cells Impact Germline Genetic Test Results?. Blood, 2019, 134, 3698-3698.	1.4	0
53	Diagnostic Tools for Inborn Errors of Human Immunity (Primary Immunodeficiencies and Immune) Tj ETQq1 1 0.784314 rgBT /Overlode	5.3	15
54	Does matching for SNPs in the MHC gamma block in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant improve outcomes?. Human Immunology, 2018, 79, 532-536.	2.4	6

#	ARTICLE	IF	CITATIONS
55	What's in a name: are menopausal "hot flashes" a symptom of menopause or a manifestation of neurovascular dysregulation?. <i>Menopause</i> , 2018, 25, 700-703.	2.0	21
56	DNA methyltransferase expression in triple-negative breast cancer predicts sensitivity to decitabine. <i>Journal of Clinical Investigation</i> , 2018, 128, 2376-2388.	8.2	134
57	SLCO1B1 genetic variation and hormone therapy in menopausal women. <i>Menopause</i> , 2018, 25, 877-882.	2.0	16
58	Clinical UGT1A1 Genetic Analysis in Pediatric Patients: Experience of a Reference Laboratory. <i>Molecular Diagnosis and Therapy</i> , 2017, 21, 327-335.	3.8	8
59	The challenges of implementing pharmacogenomic testing in the clinic. <i>Expert Review of Pharmacoeconomics and Outcomes Research</i> , 2017, 17, 567-577.	1.4	37
60	Tumor Sequencing and Patient-Derived Xenografts in the Neoadjuvant Treatment of Breast Cancer. <i>Journal of the National Cancer Institute</i> , 2017, 109, .	6.3	61
61	Pathologic findings in breast, fallopian tube, and ovary specimens in non- BRCA hereditary breast and/or ovarian cancer syndromes: a study of 18 patients with deleterious germline mutations in RAD51C , BARD1 , BRIP1 , PALB2 , MUTYH , or CHEK2. <i>Human Pathology</i> , 2017, 70, 14-26.	2.0	11
62	Challenges in Ordering and Interpreting Pharmacogenomic Tests in Clinical Practice. <i>American Journal of Medicine</i> , 2017, 130, 1342-1344.	1.5	21
63	Clinical outcomes of HLA-DPB1 mismatches in 10/10 HLA-matched unrelated donor-recipient pairs undergoing allogeneic stem cell transplant. <i>European Journal of Haematology</i> , 2017, 99, 275-282.	2.2	11
64	Establishing and characterizing patient-derived xenografts using pre-chemotherapy percutaneous biopsy and post-chemotherapy surgical samples from a prospective neoadjuvant breast cancer study. <i>Breast Cancer Research</i> , 2017, 19, 130.	5.0	53
65	Technical Challenges and Opportunities when Implementing Pharmacogenomics Decision Support Integrated in the Electronic Health Record. <i>Studies in Health Technology and Informatics</i> , 2017, 245, 1255.	0.3	6
66	Could personalized management of menopause based on genomics become a reality?. <i>Pharmacogenomics</i> , 2016, 17, 659-662.	1.3	9
67	Implementation of Clinical Decision Support Rules to Reduce Repeat Measurement of Serum Ionized Calcium, Serum Magnesium, and N-Terminal Pro-B-Type Natriuretic Peptide in Intensive Care Unit Inpatients. <i>Clinical Chemistry</i> , 2016, 62, 824-830.	3.2	21
68	Relationship of Genetic Variation in the Serotonin Transporter Gene (SLC6A4) and Congenital and Acquired Cardiovascular Diseases. <i>Genetic Testing and Molecular Biomarkers</i> , 2015, 19, 115-123.	0.7	3
69	Exome sequencing reveals frequent deleterious germline variants in cancer susceptibility genes in women with invasive breast cancer undergoing neoadjuvant chemotherapy. <i>Breast Cancer Research and Treatment</i> , 2015, 153, 435-443.	2.5	26
70	Acetaminophen-NAPQI Hepatotoxicity: A Cell Line Model System Genome-Wide Association Study. <i>Toxicological Sciences</i> , 2011, 120, 33-41.	3.1	61
71	Single Nucleotide Polymorphisms (SNPs) in Genes for Glutathione-Related Metabolism, Cyclin D1, and DNA Repair As Predictive Biomarkers in Mantle Cell Lymphoma Patients Treated with R-HyperCVAD with Ten Year Clinical Follow-up,. <i>Blood</i> , 2011, 118, 3650-3650.	1.4	0
72	Glutathione Pathway Genetic Polymorphisms and Lung Cancer Survival After Platinum-Based Chemotherapy. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2010, 19, 811-821.	2.5	42

#	ARTICLE	IF	CITATIONS
73	Glutathione <i>S</i> -Transferase T1 and M1: Gene Sequence Variation and Functional Genomics. Clinical Cancer Research, 2007, 13, 7207-7216.	7.0	69